Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Ono Pharmaceutical Partner for Autoimmune Diseases Drug Discovery

NEW YORK – Twist Bioscience said on Thursday that it has entered an agreement with Japanese company Ono Pharmaceutical to discover and develop novel antibodies for the treatment of autoimmune diseases.

As part of the deal, Twist will utilize its so-called "Library of Libraries" to help discover novel antibodies against targets identified by Ono. According to Twist, the Library of Libraries is an "expansive collection of synthesized antibody libraries based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of drug targets."

Ono, on the other hand, will use the Twist biopharma solutions team's scientific expertise and Twist's premium project management services to evaluate new targets and generate comprehensive discovery campaigns.

Under the terms of the partnership, Ono will be responsible for the development, manufacturing, and commercialization of any products resulting from the collaboration. Meanwhile, Twist will receive research fees, success-based clinical and regulatory milestones, and royalties on product sales, it said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.